You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 18, 2024

SKELAXIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Skelaxin patents expire, and when can generic versions of Skelaxin launch?

Skelaxin is a drug marketed by King Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in SKELAXIN is metaxalone. There are twenty drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the metaxalone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Skelaxin

A generic version of SKELAXIN was approved as metaxalone by SANDOZ on March 31st, 2010.

  Sign Up

Paragraph IV (Patent) Challenges for SKELAXIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SKELAXIN Tablets metaxalone 800 mg 013217 1 2004-11-04

US Patents and Regulatory Information for SKELAXIN

SKELAXIN is protected by one US patents.

Patents protecting SKELAXIN

Metaxalone products, method of manufacture, and method of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MUSCULOSKELETAL CONDITIONS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-003 Aug 30, 2002 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SKELAXIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-003 Aug 30, 2002 ⤷  Sign Up ⤷  Sign Up
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-003 Aug 30, 2002 ⤷  Sign Up ⤷  Sign Up
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-003 Aug 30, 2002 ⤷  Sign Up ⤷  Sign Up
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for SKELAXIN

See the table below for patents covering SKELAXIN around the world.

Country Patent Number Title Estimated Expiration
Canada 2626027 PRODUITS A BASE DE METAXALONE, PROCEDE DE PREPARATION ET PROCEDE D'UTILISATION (METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE) ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2007094825 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.